Objective: Partial or complete urinary obstruction caused by a tumor itself may affect renal function and the eligibility for perioperative cisplatin-based chemotherapy in patients with upper tract urothelial carcinoma. We investigated whether the status of preoperative hydronephrosis provides additional predictive information concerning changes in perioperative renal function. Methods: A total of 155 patients who underwent nephroureterectomy for upper tract urothelial carcinoma from 1997 to 2010 were identified. The association between preoperative parameters including the grade of hydronephrosis and perioperative renal function was analyzed. Results: Hydronephrosis was observed in 104 patients. The grade of hydronephrosis was 1, 2, 3 and 4 in 6 (3.9%), 25 (16.1%), 42 (27.1%) and 31 (20.0%) cases. Using a defined cutoff creatinine clearance value of !50 ml/min indicating eligibility for cisplatin-based chemotherapy, only 94 patients (60.6%) were eligible in the neoadjuvant setting. Of these 94 patients, 30 (31.9%) were judged to be ineligible in the adjuvant setting. Multivariate analysis demonstrated that patient age !70 years [P , 0.001, hazard ratio (HR) 27.9] and the absence of a higher grade hydronephrosis (P ¼ 0.013, HR 7.40) were independent risk factors for predicting patients ineligible to receive adjuvant cisplatin-based chemotherapy. The proportion of patients ineligible to receive cisplatin-based chemotherapy changed from 40.9 to 88.6% following nephroureterectomy in patients aged !70 years and those with no or a lower grade hydronephrosis. Conclusions: The status of hydronephrosis is an independent predictor of eligibility to receive adjuvant cisplatin-based chemotherapy. The information on preoperative hydronephrosis and patient age may assist in part of the decision-making when considering neoadjuvant cisplatinbased chemotherapy.
Introduction
Upper tract urothelial carcinoma (UTUC) is relatively uncommon urothelial malignancy, accounting for only 5% (1 -3) . Although nephroureterectomy (NU) with excision of a bladder cuff is the gold standard for the treatment of localized UTUC, the prognosis for patients who undergo NU remains poor due to high risk of systemic recurrence after operation. Many patients with localized UTUC are stage T3 or greater at the time of surgery (4, 5) , and at least 20 -25% of these patients might be considered to already have lymph node involvement (6 -8) . Therefore, even after radical surgery, 5-year cancer-specific survival rates ranging between 50 and 80% have been reported (9 -12) . These poor outcomes have raised questions concerning the indication of perioperative chemotherapy in an attempt to improve disease control in patients with UTUC.
Cisplatin-based chemotherapy (CBCT) is the standard regimen for patients with urothelial malignancies. The management of patients with invasive bladder cancer involves radical cystectomy and perioperative CBCT, in either the neoadjuvant or the adjuvant setting. The use of neoadjuvant CBCT for invasive bladder cancer before definitive local surgery leads to an 5% absolute improvement in the overall survival compared with surgery or radiotherapy alone (13) (14) (15) .
On the other hand, the accurate impact of perioperative CBCT on the survival of patients with UTUC is controversial as there is no randomized trial in either a neoadjuvant or an adjuvant setting. According to the same logic for the management of bladder cancer, perioperative CBCT for UTUC is often considered; however, for patients with UTUC, impaired renal function (RF) following NU may often limit the administration of CBCT if it is demonstrated to be the adjuvant setting. Several papers have evaluated changes in RF following NU (16, 17) , and reported that patient age was associated with ineligibility for CBCT in the adjuvant setting (17) . Although it is believed that RF in some patients with UTUC may be affected by the urinary obstruction caused by UTUC itself, previous studies have not fully evaluated the impact of urinary obstruction caused by UTUC itself in postoperative RF.
In the present study, we retrospectively reviewed the data of 155 patients who underwent NU for locally advanced UTUC at our institution. We examined the changes in perioperative RF and evaluated preoperative indicators, such as the status of their preoperative hydronephrosis, for predicting patient eligibility for perioperative CBCT.
PATIENTS AND METHODS
The medical records from 1997 to 2010 archived at Keio University Hospital were reviewed. During this period, more than 200 patients underwent NU for locally advanced UTUC. Fifteen patients for whom we do not have the data of preoperative computerized tomography (CT) and/or magnetic resonance imaging (MRI) were excluded from the study. After excluding 31 patients with renal caliceal tumors in whom hydronephrosis of tumors was sometimes partial, we identified a total of 158 patients in our study population. Of the 158 patients, 3 who underwent neoadjuvant CBCT that might have an effect on subsequent RF were excluded, and the remaining 155 patients were included in the subsequent analyses. The independent parameters for evaluating the changes in perioperative RF were age, gender, tumor location, clinical T category and the status of preoperative hydronephrosis.
Tumor location and clinical T category were determined by CT and/or MRI preoperatively. Based on the location of the dominant lesion, the tumor location was divided into two categories: the renal pelvis or ureter. Using CT and/or MRI, preoperative hydronephrosis was graded from 0 to 4 according a classification system reported previously: Grade 0, no calyx or pelvic dilation; Grade 1, tumors with pelvic dilation only; Grade 2, mild calyx dilation; Grade 3, tumors with severe calyx dilation and delayed enhancement and Grade 4, calyx dilation accompanied by renal parenchyma atrophy (18) . Two genitourinary radiologists who were blinded to clinical data re-reviewed all radiological examinations in consensus.
Perioperative RF was estimated using three formulas (19) . Creatinine clearance (CrCl) was estimated from serum creatinine (SCr) using the Cockroft -Gault (C-G) formula:
, which is the most widely used equation. For comparison purposes, we also calculated CrCl using the Jelliffe formula:
, and estimated the glomerular filtration rate (GFR) using the four-variable modification of diet in renal disorder (MDRD) study equation
The SCr value obtained the closest to the time of NU was considered to be the preoperative value. The nadir postoperative SCr level was designated as the lowest documented value between 8 days to 3 months following NU. A minimum of 8 days following NU was chosen to decrease the rate of spuriously low SCr measurements due to perioperative intravenous hydration. In the present study, patients with a CrCl of !50 ml/min were defined as being eligible to receive CBCT, and we investigated the changes in postoperative RF as well as their eligibility for CBCT.
The associations between perioperative RF and the patient clinicopathological parameters were analyzed and validated using the x 2 test or Mann -Whitney U-test. Multivariate analysis was performed using logistic regression methodology to identify factors associated with postoperative worsening RF. Differences among groups were regarded as significant when P , 0.05. These analyses were performed using the SPSS, version 17.0, statistical software package.
RESULTS
The median age of all cohorts was 69 years (range, 36 -91 years). Males accounted for 78.7% (122 patients) and females accounted for 21.3% (33 patients). Table 1 presents a summary of the clinicopathological parameters in the 155 patients. Perioperative RF was estimated using three formulas (C -G, Jelliffe and MDRD). The preoperative RF values (mean + SD) for C -G (ml/min), Jelliffe (ml/min) and MDRD (ml/min/1.73 m 2 ) were 61. (3) 203 absolute values decreased after operation (P , 0.001) for all three formulas. Preoperative hydronephrosis was evaluated by CT in 149 patients (96.1%) and by MRI in 6 patients (3.9%). Preoperative hydronephrosis was observed in 104 patients (67.1%). The grade was 1, 2, 3 and 4 in 6 (3.9%), 25 (16.1%), 42 (27.1%) and 31 (20.0%) cases, respectively. Using the defined cut-off CrCl value of !50 (ml/min) indicating eligibility for CBCT, only 94 patients (60.6%) were judged to be eligible in the neoadjuvant setting. The clinicopathological parameters in the 155 patients according to eligibility for neoadjuvant CBCT are listed in Table 2 . A greater proportion of patients aged 70 years or more would have already missed the opportunity to undergo neoadjuvant CBCT compared with younger patients aged ,70 years (P , 0.001). Similarly, patients with a higher grade of hydronephrosis such as grades 3 and 4 were more likely to be ineligible for neoadjuvant CBCT compared with those with a lower grade (P , 0.001).
Sixty-one patients ineligible to receive preoperative CBCT were excluded, resulting in 94 possible candidates for the neoadjuvant setting being included in further analyses. Of these 94 patients, 30 (31.9%) were judged to be ineligible to undergo adjuvant CBCT due to their worsening post-RF. Multivariate analyses demonstrated that patient age !70 years (P , 0.001, HR 27.9) and the absence of a higher grade of hydronephrosis (P ¼ 0.013, HR 7.40) were independent risk factors predicting ineligibility for adjuvant CBCT (Table 3) . Similar results were observed when we defined other cut-off CrCl values, such as the CrCl value of !60 (ml/min) or !40 (ml/min), indicating eligibility for CBCT. Furthermore, in order to exclude a possible influence of patient age on estimated RF, we also performed multivariate analysis controlling for gender, tumor location, clinical T category and the grade of hydronephrosis. In our population, multivariate analysis still revealed that the absence of a higher grade hydronephrosis (P ¼ 0.002, HR 8.78) was an independent predictor for the ineligibility for adjuvant CBCT.
We then stratified the 155 patients by age and the grade of hydronephrosis according to their ineligibility for CBCT (Fig. 1A and B) . A greater proportion of patients aged !70 years were judged to be ineligible to undergo adjuvant CBCT compared with younger patients. Similarly, patients with no or a lower grade hydronephrosis were more likely to be ineligible for adjuvant CBCT when compared with those with a higher grade hydronephrosis.
Next, we classified all patients into four subgroups according to the age and preoperative hydronephrosis status: Group A, age ,70 years with Grade 0, 1 or 2 hydronephrosis; Group B, age ,70 years with Grade 3 or 4 hydronephrosis; Group C, age !70 years with Grade 0, 1 or 2 CBCT, cisplatin-based chemotherapy; CrCl, creatinine clearance. (Fig. 2A) . The proportion of patients ineligible to undergo CBCT following NU changed from 39.4 to 58.1% overall, from 5.3 to 21.1% in Group A, no changed proportion in Group B, from 40.9 to 88.6% in Group C and from 86.0 to 90.7% in Group D (Fig. 2B) .
DISCUSSION
In the present study, we retrospectively investigated the changes in perioperative RF in 155 patients who underwent NU for UTUC, and examined preoperative indicators for predicting patient eligibility for perioperative CBCT. Using the defined cut-off CrCl value of !50 (ml/min) to indicate eligibility for CBCT, multivariate analysis adjusted for age, gender, tumor location, clinical stage and preoperative hydronephrosis showed that patient age and the status of hydronephrosis were independent risk factors predicting eligibility for adjuvant CBCT. According to these indicators, the proportion of patients eligible for CBCT dramatically decreased after surgery in patients aged !70 years and with no or a lower grade hydronephrosis. For the management of patients with invasive bladder cancer, a 25 and 40% relative risk reduction in all-cause and cancer-specific mortality, respectively, was observed in patients receiving three cycles of methotrexate, vinblastine, doxorubicin and cisplatin before radical cystectomy compared with a surgical procedure alone (13) . A 5% absolute improvement in survival was also reported when neoadjuvant CBCT was added to radical cystectomy or primary radiotherapy (14, 15) . Although little evidence suggests that the biology of UTUC differs from that of bladder cancer, neoadjuvant CBCT has the potential to play a significant role in UTUC. Contemporary studies imply a therapeutic benefit of neoadjuvant CBCT (5, 20) .
However, unlike bladder cancer, it is difficult to identify the presence of muscle invasion and tumor grade accurately before NU. Although there has been some success in stage prediction based on imaging studies and tumor grade at biopsy using ureteroscopy, uncertainty rates are still on the order of 30 -40% (21) . Abdominal imaging with CT and/or MRI is prone to understaging, and excretory urography or retrograde pyelography provide limited staging information (22, 23) . During ureteroscopy, the small, delicate instrumentation used for biopsy, coupled with the risk of perforation of the thin, muscular layers of the renal pelvis and ureteral walls, may preclude adequate tissue sampling, unlike transurethral resection of bladder tumors. Biopsy-demonstrated, high-grade disease alone has an 66% positive predictive value for predicting high-stage disease (24) . Due to these inaccuracies in preoperative prediction of pathological characteristics, perioperative CBCT for patients with UTUC has been demonstrated in the adjuvant setting (25, 26) . However, Jpn J Clin Oncol 2012;42(3) 205 a worse RF following NU often limits the effective dose and/or administration of adjuvant CBCT. Concerning the renal insufficiency resulting from NU, Lane et al. reported changes in perioperative RF in patients with UTUC and investigated the proportion of patients eligible for adjuvant CBCT. They reported that chronic kidney disease was already present in 175 (52%) of 336 patients with UTUC at the time of diagnosis, and the proportion of patients with chronic kidney disease increased to 78% resulting from NU with a median 21% relative reduction in RF (16) . On the other hand, Kaag et al. have described preoperative indicators for predicting changes in RF following NU (17) , and reported that patient age, especially age !70 years, rendered a patient ineligible for cisplatin therapy following NU. The results of previous reports were similar to the present data. However, while RF may be affected due to urinary obstruction caused by an upper urinary tract tumor itself; previous studies still did not provide an appropriate indicator for predicting post-RF concerning urinary obstruction caused by UTUC itself. To the best of our knowledge, this is the first paper that evaluates the accurate impact of preoperative hydronephrosis on perioperative RF in patients with UTUC.
Basically, candidates for systemic chemotherapy should be determined not only by oncologic parameters such as pathological features, but also the patient's performance status and patient co-morbidity. Thus, our findings may only provide a possible timing of perioperative CBCT for patients with UTUC. However, our data clearly show that a greater proportion of patients aged !70 years and with no or a lower grade of hydronephrosis had missed an opportunity to undergo adjuvant CBCT due to worse RF resulting following NU. We believe that this information may assist in part of the decision-making in the preoperative management, including neoadjuvant chemotherapy, of UTUC.
This study has some limitations. It was performed in a retrospective manner and in a limited number of patients. In addition, patients who were not evaluated by CT and/or MRI preoperatively were excluded from multivariate analysis.
CONCLUSION
The status of preoperative hydronephrosis was an independent risk factor predicting eligibility for CBCT in an adjuvant setting. The greater proportion of patients aged !70 years and with no or a lower grade of hydronephrosis is associated with a high risk of missing an opportunity to undergo adjuvant CBCT resulting from NU. These indicators may assist in part of the decision-making when considering neoadjuvant chemotherapy in patients with UTUC.
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